Cover Page. The handle holds various files of this Leiden University dissertation.

Similar documents
6.1 Extended family screening

Beta Thalassemia Frequency in Bahrain: A Ten Year Study. Shaikha Salim Al-Arrayed, MB,ChB, DHCG, PhD*

Thalassemias. Emanuela Veras, M.D. 01/08/2006

Haemoglobin BY: MUHAMMAD RADWAN WISSAM MUHAMMAD

Case Report Iron Depletion: An Ameliorating Factor for Sickle Cell Disease?

Comprehensive Hemoglobin Analysis HBA1/2 (

SICKLE CELL DISEASE. Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH. Assistant Professor FACULTY OF MEDICINE -JAZAN

Should Universal Carrier Screening be Universal?

Epidemiology, Care and Prevention of Hemoglobinopathies

Thalassaemia and Abnormal Haemoglobins in Pregnancy

Report of Beta Thalassemia in Newar Ethnicity

Quiz. What percentage of the world s population is a carrier of a hemoglobinopathy? Hemoglobinopathies in Pregnancy 1-2% 5-7% 8-12% 10-15%

Dr. Ayman Mohsen Mashi, MBBS Consultant Hematology & Blood Transfusion Department Head, Laboratory & Blood Bank King Fahad Central Hospital, Gazan,

Evaluation of hemoglobinopathy screening results of a six year period in Turkey

Anemia s. Troy Lund MSMS PhD MD

George R. Honig Junius G. Adams III. Human Hemoglobin. Genetics. Springer-Verlag Wien New York

MOLECULAR BASIS OF THALASSEMIA IN SLOVENIA

Neonatal Screening for Genetic Blood Diseases. Shaikha Al-Arayyed, PhD* A Aziz Hamza, MD** Bema Sultan*** D. K. Shome, MRCPath**** J. P.

Genetics of Thalassemia

The Beats of Natural Sciences Issue 3-4 (September-December) Vol. 3 (2016)

JMSCR Vol 06 Issue 01 Page January 2018

Thalassemias:general aspects and molecular pathology

Screening for haemoglobinopathies in pregnancy

Hemolytic anemias (2 of 2)

Corporate Medical Policy

Diagnostic difficulties in prevention and control program for thalassemia in Thailand: atypical thalassemia carriers

THALASSEMIA AND COMPREHENSIVE CARE

Genetic Modifiers of Sickle Cell Disease Severity. Kunle Adekile, MD, PhD Professor Department of Pediatrics Kuwait University

Article Preimplantation diagnosis and HLA typing for haemoglobin disorders

Counselling and prenatal diagnosis. Antonis Kattamis, Greece

DONE BY : RaSHA RAKAN & Bushra Saleem

HEMOLYTIC ANEMIA DUE TO ABNORMAL HEMOGLOBIN SYNTHESIS

Proposed low-cost premarital screening program for prevention of sickle cell and thalassemia in Yemen Hafiz Al-Nood 1 Abdulrahman Al-Hadi 2

Agro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17

REVIEW OF LITERATURE. Review of literature:

Dr.Abdolreza Afrasiabi

In adults, the predominant Hb (HbA) molecule has four chains: two α and two β chains. In thalassemias, the synthesis of either the α or the β chains

Hematologic Features of Alpha Thalassemia Carriers

4 Fahed Al Karmi Sufian Alhafez Dr nayef karadsheh

Cover Page. The handle holds various files of this Leiden University dissertation.

HEMOGLOBIN ELECTROPHORESIS DR ARASH ALGHASI SHAFA HOSPITAL-AHWAZ

Thalassaemia and other haemoglobinopathies

Expanded Carrier Screening: What s Best?

High Hemoglobin F in a Saudi Child Presenting with Pancytopenia

Cover Page. The handle holds various files of this Leiden University dissertation.

SICKLE CELL BROCHURE

Thalassemia. By: Rebecca Chang (Period 6)

The Thalassemias in Clinical Practice. Ashutosh Lal, MD Director Comprehensive Thalassemia Program UCSF Benioff Children s Hospital Oakland

Prevalence of Thalassemia in Patients With Microcytosis Referred for Hemoglobinopathy Investigation in Ontario A Prospective Cohort Study

Unraveling Hemoglobinopathies with Capillary Electrophoresis

got anemia? IT COULD BE THALASSEMIA TRAIT

Hemoglobinopathies Diagnosis and management

helpful guide Carrier Testing for Common Genetic Diseases Hemoglobinopathies Cystic Fibrosis Spinal Muscular Atrophy Fragile X

PATIENT EDUCATION. carrier screening INFORMATION

Thalassemia Maria Luz Uy del Rosario, M.D.

Next Generation Sequencing as a tool for breakpoint analysis in rearrangements of the globin-gene clusters

How to Write a Life Care Plan for a Child with Hemoglobinopathy

NEWBORN SCREENING FOR SICKLE CELL DISEASE Progress Towards Improved Outcomes for Children and Families

The pros and cons of the fourth revision of thalassaemia screening programme in Iran

Lesson Overview. Human Genetic Disorders. Lesson Overview Human Genetic Disorders

Detection of Hemaglobinopathies in Anemic Children by HPLC method A Hospital Based Study

Below are the sections of the DNA sequences of a normal hemoglobin gene and the mutated gene that causes sickle cell disease.

Community Genetics. Hanan Hamamy Department of Genetic Medicine & Development Geneva University Hospital

Carrying Beta Thalassaemia A carrier can use this booklet to

Genetic Modulation on the Phenotypic Diversity of Sickle Cell Disease

VALIDATION OF OSMOTIC FRAGILITY TEST AND DICHLOROPHENOL INDOPHENOL PRECIPITATION TEST FOR SCREENING OF THALASSEMIA AND Hb E

Gamma gene expression in haemoglobin disorders

Haemoglobinopathies case studies 11 th Annual Sickle Cell and Thalassaemia Conference October 2017

AGE AT MENARCHE AND FIRST CONCEPTION IN SICKLE CELL HEMOGLOBINOPATHY

4 Jumana Jihad Dr. Ahmad Mansour Dr. Ahmad Mansour

The Making of the Fittest: Natural Selection in Humans

EVOLVE CARRIER GENETIC SCREENS. Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW.

Beta Thalassemia Case Study Introduction to Bioinformatics

Journal of Medical Science & Technology

Detecting and Reporting Alpha Thalassemia In Newborns

The Making of the Fittest: Natural Selection in Humans

HbF<2% 95-98% H b A %

The Challenging Diagnosis of Treacherous Hemoglobinopathies

Sickle Cell Anemia A Fictional Reconstruction Answer Key

HEMOGLOBINOPATHIES LECTURE OUTLINE. An overview of the structure of hemoglobin. Different types of hemoglobin. Definition of hemoglobinopathies

Assessing the follow-up of BART hemoglobin reported by the Wisconsin Newborn Screening Laboratory

Natural Selection In Humans (Sickle Cell Anemia)

Biology 2C03: Genetics What is a Gene?

ETHICAL ISSUES IN REPRODUCTIVE MEDICINE

Evaluation of the Molecular basis of KLF1 Gene in Iranian Thalassemia individuals with borderline hemoglobin A2

The Prevalence and Heterogeneity of Beta Thalassemia Mutations in The Western Maharashtra Population: A Hospital Based Study

Chem*3560 Lecture 4: Inherited modifications in hemoglobin

Clinical Policy: Allogenic Hematopoietic Cell Transplants for Sickle Cell Anemia and β-thalassemia

BRITISH BIOMEDICAL BULLETIN

HPLC profile of sickle cell disease in central India

Sickle Cell Anemia. Sickle cell anemia is an inherited disorder of the blood which occurs when just one base pair substitution

USING RETICULOCYTE INDICES TO IDENTIFY α-thalassemia A PRELIMINARY REPORT

Dr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW

Pitfalls in the premarital testing for thalassaemia

Human Genetic Diseases (Ch. 15)

Type and frequency of hemoglobinopathies, diagnosed in the area of Karachi, in Pakistan

Lesson Overview. Human Genetic Disorders. Lesson Overview Human Genetic Disorders

The Distribution of Human Differences. If all this genetic variation is so recent and continuous, why do we think of it in categorical terms?

Index. Note: Page numbers of article titles are in boldface type.

HAEMOGLOBINOPATHIES. Editing file. References: 436 girls & boys slides 435 teamwork slides. Color code: Important. Extra.

Transcription:

Cover Page The handle http://hdl.handle.net/1887/35456 holds various files of this Leiden University dissertation. Author: Hassan, Suha Mustafa Title: Toward prevention of Hemoglobinopathies in Oman Issue Date: 2015-09-22

Summary/Samenvatting

Summary Hemoglobinopathies (HBP) are the most common autosomal recessive genetic disorder world-wide and in particular in the African continent, India, Far East, the Mediterranean and Middle Eastern countries including Oman. HBP can be the consequence of mutations causing structural abnormality in the hemoglobin molecule (abnormal hemoglobins) or a reduction/ abolishment in the overall synthesis of the hemoglobin components (thalassemia), leading to anemia. Carriers are usually asymptomatic but carrier couples are at 25% risk of getting a severely affected child. One of the main challenges faced by most Arab countries and by Oman in particular are the high prevalence rates of HBP [mainly sickle cell disease (SCD) and beta thalassemia major (TM)]. The prevalence is high in these areas due to the positive selection in the presence of malaria tropica. Moreover, due to consanguinity, a socio-cultural habit, the incidence of severely affected children is high in Oman. Around 10 % of Omanis are SCD carriers, 3 % carry a defect causing β-thalassemia and at least half of the population are carriers of α-thalassemia. Although the disease could be treated, there is no definite cure until now except for a matched bone marrow transplant. Public health authorities have focused not only on state of the art management and patient care but also on prevention. National premarital clinics aiming at identifying partners at risk prior reproduction and offering genetic counselling and prevention have been working in the country for the last decade. The focus of this thesis is to study the molecular spectrum of HBP and the associated genetic determinants to work towards the development of prevention strategies for severe HBP s in Oman. In order to develop and improve risk assessment during pre-matrimonial counselling we have defined the molecular spectrum of the disease all around the country. In Chapter 4, we present a first study on 87 un-related Omanies either heterozygous or homozygous for beta thalassemia mainly coming from four different regions in Oman. We found 11 beta determinants with at least 56% of the cases with heterozygosity or homozygositiy for the common alphathalassemia deletions; alpha 3.7kb and/or alpha 4.2kb. We have further extended our analysis to reveal a broader spectrum of beta globin gene mutations in Chapter 5, studying larger number of subjects (n=446) of different tribal origin, covering all the seven regions in the country. Thirty-two different beta mutations were identified with 11 being described for the first time among the Omani population. We then analysed the alpha globin gene defects in details in Chapter 7. A total of (n=634) subjects were divided into seven groups based on their hematological readings and were analysed at the molecular level. Twenty-one different alpha defects were categorised of which 15 were described for the first time among Omanies with two defects presumed to be new. We further reported in Chapter 6 two new cases among the Omani. The first is an alpha variant found in a consanguineous couple that probably resulted in a severe fetal hemolytic anemia while the second is a novel β-globin gene promoter mutation associated with borderline/slightly elevated HbA 2, indicating a very mild de novo β + thalassemia mutation. The high heterogeneity of common, rare and novel beta- and alpha- globin genes defects observed among Omanies (Chapters 4,5,6 and 7), outlines the historic migration pattern and the mixed ethnicity among the population and emphasize the necessity of implementing DNA testing during pre-marital screening for accurate risk prediction and genetic counselling 197

198 especially when both beta and alpha defects coexist making genotype prediction more complex and herewith providing the state of the art for prenatal diagnosis in the future. In Chapter 8, we looked at the interfering effect of factors such as delta gene defect or iron deficiency that may influence HbA 2 measurement in the Omanies and herewith the diagnosis of beta thalassemia trait. This is particularly important during beta-thalassemia carrier screening because coexisting delta thalassemia defect with a beta thalassemia carrier status can normalise HbA 2 level and preclude a correct diagnosis. For that, we investigated 33 cases with low HbA 2 levels. Ten different defective delta alleles of which two are reported for the first time in literature were categorised in 20 subjects. The characterization of the delta-gene mutation spectrum is bound to make premarital screening and genetic counseling more reliable in the Omani population screened for beta thalassemia. Patients with sickle cell disease (SCD) may show a strong variability in morbidity and response to therapy from case to case, depending from the often complex genotypes and haplotypes. The classical associated determinants were investigated in Chapters 9,10 and 11. In Chapter 9, the haplotype/sub-haplotype and phenotype in SCD patients (n=125) was investigated. A total of 11 different haplotype combinations were identified with the Asian haplotype being the most common and associated with a milder clinical form. In Chapter 10, a cohort of (n=52) SCD patients treated with hydroxyurea (HU) were tested for their response to HU based on their XmnI polymorphism. Patients homozygous or heterozygous for Xmn I (T/T or T/C) showed better response and improvement in clinical phenotype than patients bearing the (C/C) genotype. In Chapter 11, we assessed if presence or absence of alpha thalassemia in the same 125 SCD patients with identical beta genotype and haplotypes can ameliorate disease severity. We found that alpha thalassemia improves the overall hematological conditions but amelioration of the general disease severity is only noticed when compared in cohorts of the same haplotype. We conclude from these correlative studies that neither the haplotype or sub-haplotype nor the XmnI polymorphism nor alpha-thalassemia alone appears to be fully associated with the variable clinical phenotypes in SCD and that presumably other external factors can play a role in the different expression of the disease. Nevertheless, identifying genetic determinants is necessary for prognostic purposes, accurate diagnosis and planning for the best-tailored treatment to the affected children. In Chapter 12, we tested the application of Ion Torrent PGM as a diagnostic ultra highthoughput sequencing method for beta globin gene during beta thalassemia screening. We scanned a total of 297 Omani cases using a barcoded uni-directional sequence methodology and reliably identified beta-thal mutations in hundreds of patients simultaneously. Our results show that ion torrent can replace Sanger sequencing in the future and is a powerful diagnostic method to detect HBP carriers and carriers of other common genetic disorders in a national screening setting and that these molecular methods may become more practical if financially affordable. Pre-matrimonial counselling, although thorough, is the only formal option available in Oman to couples at risk. This leaves only two options for couples whenever a presumed genetic risk has been suspected: to change the choice of partner or to continue with the marriage and hope for a healthy child from each pregnancy. Therefore the most effective prevention

method for HBP disorders thus far seems to be also in Oman, is prenatal diagnosis followed by the option of pregnancy termination. In Chapter 13 we investigated the attitude of 35 Omani couples at risk towards prenatal diagnosis and medical abortion. Although the majority would have accepted prenatal diagnosis if the service was available in the country, pregnancy termination was greatly influenced by the Islamic view as interpreted in the country by the main religious Muftee. However, prenatal diagnosis may be eventually considered in Oman with improved public awareness and once the public health authorities have reached a sensible agreement with religious authorities, as has been the case in other Muslim countries. In conclusion, while providing tools for a better care and a better insight on the management of these severe diseases in Oman, our results will hopefully facilitate the prevention of HBP in the country. 199